Neurocrine Biosciences Inc (NASDAQ:NBIX) Beats Q2 2025 Earnings Estimates but Stock Drops 8.6% on Investor Concerns

Neurocrine Biosciences Inc (NASDAQ:NBIX) reported its second-quarter 2025 financial results, delivering revenue and earnings per share (EPS) that exceeded analyst expectations. However, the stock faced significant downward pressure in after-hours trading, declining approximately 8.6%, suggesting investor concerns despite the beat.

Key Financial Highlights vs. Estimates

• Revenue: Reported at $687.5 million, surpassing the consensus estimate of $663.5 million, reflecting a 3.6% beat.
• EPS: Came in at $1.06, above the estimated $0.97, marking a 9% beat.
• Full-Year 2025 Revenue Guidance: The company narrowed its net product sales forecast for INGREZZA® to $2.5 - $2.55 billion, which aligns closely with analyst sales expectations of $2.738 billion for the full year.

Market Reaction & Performance Context

Despite the earnings and revenue beat, the sharp after-hours decline indicates investor apprehension, possibly tied to:

• Guidance Interpretation: While the narrowed INGREZZA sales outlook is in line with expectations, the lack of an upward revision may have disappointed some investors hoping for stronger growth signals.
• Recent Stock Performance: Prior to the earnings release, NBIX had shown modest gains over the past month (+6.76%) and two weeks (+2.25%), suggesting the market may have priced in higher expectations.

Press Release Takeaways

• INGREZZA® Sales Growth: Net product sales for the drug reached $624 million in Q2, contributing to total net product sales of $682 million, up 17% year-over-year.
• Pipeline & Commercial Execution: The company continues to focus on its neuroscience portfolio, with no major pipeline updates disclosed in this release.

Looking Ahead

Analysts project Q3 2025 revenue at $1.4 billion and sales of $730.2 million, which will be a key benchmark for Neurocrine’s continued execution. The full-year revenue estimate stands at $3.99 billion, implying steady growth if met.

For a deeper dive into Neurocrine Biosciences’ earnings and estimates, visit the earnings page.

Disclaimer: This article is for informational purposes only and does not constitute investment advice.